Endometriosis Drugs Market by Product, RoA, and Geography - Global Forecast & Analysis 2019-2023
SKU ID :TNV-14050748 | Published Date: 30-Sep-2019 | No. of pages: 159Description
TOC
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
• PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Hormone therapy - Market size and forecast 2018-2023
• Analgesics - Market size and forecast 2018-2023
• Market opportunity by product
PART 07: MARKET SEGMENTATION BY ROA
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Strategic alliances
• Robust pipeline
• Availability of patient-assistance programs
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie Inc.
• Allergan Plc
• AstraZeneca Plc
• Bayer AG
• Johnson & Johnson Services Inc.
• Mayne Pharma Group Ltd.
• Merck & Co., Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
PART 15: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Hormone therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Hormone therapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: Analgesics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Analgesics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Market segmentation by RoA: Overview
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Side effects of OCPs used for treatment of endometriosis
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Drug development pipeline late-stage molecules for treatment of endometriosis
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: AbbVie Inc. - Vendor overview
Exhibit 52: AbbVie Inc. - Business segments
Exhibit 53: AbbVie Inc. - Organizational developments
Exhibit 54: AbbVie Inc. - Geographic focus
Exhibit 55: AbbVie Inc. - Key offerings
Exhibit 56: AbbVie Inc. - Key customers
Exhibit 57: Allergan Plc - Vendor overview
Exhibit 58: Allergan Plc - Business segments
Exhibit 59: Allergan Plc - Organizational developments
Exhibit 60: Allergan Plc - Segment focus
Exhibit 61: Allergan Plc - Key offerings
Exhibit 62: Allergan Plc - Key customers
Exhibit 63: AstraZeneca Plc - Vendor overview
Exhibit 64: AstraZeneca Plc - Business segments
Exhibit 65: AstraZeneca Plc - Organizational developments
Exhibit 66: AstraZeneca Plc - Geographic focus
Exhibit 67: AstraZeneca Plc - Key offerings
Exhibit 68: AstraZeneca Plc - Key customers
Exhibit 69: Bayer AG - Vendor overview
Exhibit 70: Bayer AG - Business segments
Exhibit 71: Bayer AG - Organizational developments
Exhibit 72: Bayer AG - Geographic focus
Exhibit 73: Bayer AG - Segment focus
Exhibit 74: Bayer AG - Key offerings
Exhibit 75: Bayer AG - Key customers
Exhibit 76: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 77: Johnson & Johnson Services, Inc. - Business segments
Exhibit 78: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 79: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 80: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 81: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 82: Johnson & Johnson Services, Inc. - Key customers
Exhibit 83: Mayne Pharma Group Ltd. - Vendor overview
Exhibit 84: Mayne Pharma Group Ltd. - Business segments
Exhibit 85: Mayne Pharma Group Ltd. - Organizational developments
Exhibit 86: Mayne Pharma Group Ltd. - Geographic focus
Exhibit 87: Mayne Pharma Group Ltd. - Segment focus
Exhibit 88: Mayne Pharma Group Ltd. - Key offerings
Exhibit 89: Mayne Pharma Group Ltd. - Key customers
Exhibit 90: Merck & Co. Inc. - Vendor overview
Exhibit 91: Merck & Co. Inc. - Business segments
Exhibit 92: Merck & Co. Inc. - Organizational developments
Exhibit 93: Merck & Co. Inc. - Geographic focus
Exhibit 94: Merck & Co. Inc. - Segment focus
Exhibit 95: Merck & Co. Inc. - Key offerings
Exhibit 96: Merck & Co. Inc. - Key customers
Exhibit 97: Pfizer Inc. - Vendor overview
Exhibit 98: Pfizer Inc. - Business segments
Exhibit 99: Pfizer Inc. - Organizational developments
Exhibit 100: Pfizer Inc. - Geographic focus
Exhibit 101: Pfizer Inc. - Segment focus
Exhibit 102: Pfizer Inc. - Key offerings
Exhibit 103: Pfizer Inc. - Key customers
Exhibit 104: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 105: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 106: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 107: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 108: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 109: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 111: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 112: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 116: Validation techniques employed for market sizing
Exhibit 117: Definition of market positioning of vendors
Tables & Figures
Companies
AbbVie Inc.
Allergan Plc
AstraZeneca Plc
Bayer AG
Johnson & Johnson Services Inc.
Mayne Pharma Group Ltd.
Merck & Co., Inc.
Pfizer Inc.
Takeda Pharmaceutical Co. Ltd.
Teva Pharmaceutical Industries Ltd
- PRICE
-
$2500$4000